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OBJECTIVE—To investigate whether enterovirus infections
predict progression to type 1 diabetes in genetically predisposed
children repeatedly positive for islet autoantibodies.
RESEARCH DESIGN AND METHODS—Since 1993, the Dia-
betes and Autoimmunity Study in the Young (DAISY) has fol-
lowed 2,365 genetically predisposed children for islet
autoimmunity and type 1 diabetes. Venous blood and rectal
swabs were collected every 3–6 months after seroconversion for
islet autoantibodies (against GAD, insulin, or insulinoma-associ-
ated antigen-2 [IA-2]) until diagnosis of diabetes. Enteroviral
RNA in serum or rectal swabs was detected using reverse
transcriptase PCR with primers speciﬁc for the conserved 5
noncoding region, detecting essentially all enterovirus serotypes.
RESULTS—Of 140 children who seroconverted to repeated
positivity for islet autoantibodies at a median age of 4.0 years, 50
progressed to type 1 diabetes during a median follow-up of 4.2
years. The risk of progression to clinical type 1 diabetes in the
sample interval following detection of enteroviral RNA in serum
(three diabetes cases diagnosed among 17 intervals) was signif-
icantly increased compared with that in intervals following a
negative serum enteroviral RNA test (33 cases diagnosed among
1,064 intervals; hazard ratio 7.02 [95% CI 1.95–25.3] after adjust-
ing for number of autoantibodies). Results remained signiﬁcant
after adjustment for ZnT8-autoantibodies and after restriction to
various subgroups. Enteroviral RNA in rectal swabs was not
predictive of progression to type 1 diabetes. No evidence for viral
persistence was found.
CONCLUSIONS—This novel observation suggests that progres-
sion from islet autoimmunity to type 1 diabetes may increase
after an enterovirus infection characterized by the presence of
viral RNA in blood. Diabetes 59:3174–3180, 2010
T
ype 1 diabetes results from destruction of the
insulin-producing -cells in the pancreatic islets
(1). The majority of patients carry the HLA
DRB1*03-DQB1*0201 or DRB1*04-DQB1*0302
susceptibility haplotype or both, but these are not sufﬁ-
cient for development of disease. For many years, viral
infections have been suspected to play a role, but the
speciﬁc etiologic agent(s) in human type 1 diabetes re-
mains elusive. While several viruses have been linked to
type 1 diabetes, seroepidemiology, histopathology, animal
studies, and in vitro experiments have provided the stron-
gest overall evidence for enteroviruses, although results
have been somewhat conﬂicting and not conclusive (2–4).
Autoantibodies to islet autoantigens are present for
years prior to diagnosis of type 1 diabetes (1), and
prospective studies testing whether enterovirus could
predict islet autoantibodies have yielded conﬂicting re-
sults, with positive results in Finnish studies (5–7) and no
association found elsewhere (8,9).
Results from animal models suggested that viral infec-
tions usually cannot initiate the autoimmune disease pro-
cess leading to diabetes but may accelerate an already
initiated disease process. Studies in various strains of
NOD mice have shown that enteroviral infections may
accelerate the progression to diabetes only if they occur
after autoreactive T-cells have already accumulated in the
islets (10–13). In an attempt to evaluate for the ﬁrst time
whether such a general model of disease progression
rather than initiation by enteroviruses applies to human
type 1 diabetes, we tested whether enteroviral infections
predict progression to type 1 diabetes in children repeat-
edly positive for islet autoantibodies.
RESEARCH DESIGN AND METHODS
From 1993 to 2004, children born at St. Joseph’s Hospital in Denver carrying
HLA genotypes that confer increased risk for type 1 diabetes and siblings or
offspring of people with type 1 diabetes (regardless of their genotype),
identiﬁed from the Barbara Davis Center for Childhood Diabetes, were
enrolled in the Diabetes Autoimmunity Study in the Young (DAISY). Informed
consent was obtained from parents of all children, and the study was
approved by the Colorado Multiple Institutional Review Board. Children were
followed longitudinally from soon after birth and screened for islet autoanti-
bodies at ages 9, 15, and 24 months and annually thereafter. Siblings or
offspring of individuals with type 1 diabetes were enrolled after 9 months of
age (median age 1.33 years [range 0.02–7.9]). Children who tested positive for
islet autoantibodies were scheduled for more frequent follow-up, with visits at
3–6 month intervals.
The current study is a cohort analysis of all children who tested positive for
one or more islet autoantibody on two or more consecutive clinic visits and
provided at least one sample for enterovirus testing during follow-up for type
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formed. A batch of samples collected 1993–2004 was sent for enterovirus
testing in 2005, and another batch of samples collected during 2005–June 2007
was sent in 2008. The children were further followed for diagnosis of type 1
diabetes, and the current analysis includes information on autoantibody status
and diabetes up to April 2009. Type 1 diabetes was clinically diagnosed based
on American Diabetes Association criteria (14), and details of procedures and
clinical characteristics have been described elsewhere (15,16).
Laboratory methods. HLA genotyping was done at Roche Molecular Sys-
tems, Alameda, CA, as previously described (17). Children with genotypes
DRB1*04-DQB1*0302/DRB1*03-DQB1*0201 were deﬁned as high risk,
and DRB1*04-DQB1*0302/DRB1*04-DQB1*0302 or DRB1*03/*03 or
DRB1*04-DQB1*0302/X (where X is not DRB1*04, DQB1*0302, DRB1*03,o r
DR2,DQB1*0602) was categorized as conferring moderate risk for type 1
diabetes.
At each clinic visit, venous blood and rectal swabs were collected. Blood
samples were immediately processed, aliquoted, and stored at 70°C until
testing. Rectal swabs were immediately placed in 1 ml transport medium (veal
infusion broth or M43 medium) and stored at 70°C as previously described
(8). Radioimmunoassays were used to measure serum autoantibodies to
insulin, GAD65, and IA-2 (BDC512) in George Eisenbarth’s laboratory as
previously described (18–21), with rigorous duplicate testing and conﬁrma-
tion of all positive and a subset of negative results (22). ZnT8 autoantibodies
were measured in John Hutton’s laboratory, as previously described, using a
dimeric construct incorporating monomeric forms of the COOH-terminus with
the polymorphic 325 Arg and Trp variants joined by a ﬂexible linker (23,24).
This autoantibody was measured in stored, available samples (81% of samples
with valid serum enterovirus RNA measurements).
All enterovirus assays were carried out in Heikki Hyo ¨ty’s laboratory at the
University of Tampere. All virus analyses were done blindly, without knowl-
edge of the disease status of the child. RNA was extracted from 140 l serum
and from 140 l rectal swab solution according to the manufacturer’s protocol
(QIAamp viral RNA kit; Qiagen, Hilden, Germany). The presence of enterovi-
rus RNA was detected with RT-PCR using primers speciﬁc for the 5
noncoding region conserved among Picornaviridae and subsequent enterovi-
rus-speciﬁc hybridization with lanthanide chelated probes, providing sensitive
and speciﬁc detection of practically all known enterovirus serotypes (25). All
samples with a RT-PCR signal ﬁve-fold or higher than a negative control were
tested two more times, and a sample was interpreted as positive if at least two
out of the three tests were ﬁve-fold or higher than the negative control. The 5
noncoding region of detected enteroviruses was partially sequenced, and
sequences were analyzed as described in detail in the online appendix
(http://diabetes.diabetesjournals.org/cgi/content/full/db10-0866/DC1.
Enterovirus antibodies were measured in the batch of sera collected
1993–2004, using enzyme immunoassay as described previously (26–28).
Antibodies tested were immunoglobulin M antibodies against an antigen
cocktail containing coxsackievirus B3, A16, and echovirus 11, as well as IgA
and IgG antibodies against puriﬁed coxsackievirus B4 and a synthetic entero-
virus peptide antigen, KEVPALTVETGAT-C, derived from an immunodomi-
nant region of capsid protein VP1 (29), which is a common epitope for many
enteroviruses (30). The puriﬁed viruses were heat treated to expose antigenic
determinants common for various enterovirus serotypes (26).
Deﬁnition of infection. Our primary, a priori deﬁnition of infection at a
given visit was positivity (as deﬁned above) for RT-PCR detection of entero-
virus RNA in serum or rectal swab. Additional analyses were done separately
for serum PCR and rectal PCR and for the subset of samples tested for
enterovirus antibodies. A sample was deﬁned as positive for serology if there
was a twofold or higher increase in level (optical density value) of any of the
measured antibodies in the subsequent visit (samples usually 3–6 months
apart), with an additional requirement that the signal-to-background ratio
should exceed three. Additional two-fold or higher increases in enterovirus
antibodies in a third (or later) consecutive sample drawn within 9 months of
a previous one were not counted as an additional infection. These criteria
were the same as those used in our previous prospective studies (6).
Statistical analysis. Using Cox regression, we compared the rate of progres-
sion to type 1 diabetes under two different models, which we have called the
rapid effect model and the cumulative effect model. Both treat enterovirus
infection as a time-dependent variable. In the rapid effect model, we estimated
the rate of progression to diabetes in the sample interval following detection
of enterovirus (median 4 months) compared with sample intervals where
enterovirus was not detected. The exposure status returned to zero at the next
clinic visit unless enterovirus was also found here. In the cumulative effect
model, we estimated the rate of progression to diabetes according to the
cumulative number of infections acquired during follow-up, which also allows
First degree relatives of type 1 diabetes patients 
recruited (regardless of HLA genotype) from the Barbara 
Davis Center and elsewhere in the Denver Metro area 
(1993-2004) 
N=988 
General population newborns recruited from among 
31,881 screened for HLA susceptibility genotypes 
(1993-2004) 
N=1377 
Genetically susceptible children followed with islet autoantibody 
testing* at ages 9, 12, 15, 24 months then annually† 
(1993-2009) 
N=2,365  
Children positive for ≥1 autoantibody at ≥2 consecutive visits and ≥1 
prediabetic serum and/or rectal swab sample available (1993-2007) 
N=140 
(Samples from 1295 pre-diagnostic clinic visits up to June 8, 2007  
tested for enteroviral RNA) 
Included in sensitivity analysis: 
Type 1 diabetes after being positive for ≥1 
autoantibody only once (n=4)  
Type 1 diabetes during follow-up 
to June 8, 2007 
N=41 
No type 1 diabetes during follow-up to 
April 9, 2009 
N=90  Type 1 diabetes during extended 
follow-up June 9 2007 to April 9, 2009  
N=9 
FIG. 1. Flow chart illustrating formation of the study cohort. *Samples were tested for the three islet autoantibodies: anti-GAD65, anti-insulin,
and anti–IA-2. †If positive for >1 islet autoantibody at or after 12 months of age, frequency of blood sampling was increased to every 3–6 months.
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time with zero infections, and the exposure variable increased by one at each
visit when a new infection was detected. Because few individuals had
repeated infections, the cumulative exposure variable had to be grouped (0 vs.
1 for serum RNA; 0, 1, and 2 for rectal swab RNA). The main time variable
was time from the ﬁrst clinic visit at which a child tested positive for islet
autoantibodies to type 1 diabetes diagnosis or to the most recent visit (up to
9 April 2009) at which the child was known not to have diabetes. Because
enteroviral RNA was relatively rarely detected in serum and, consequently, the
number of events during the exposed periods were limited, we also carried out
a Monte Carlo permutation test with 10,000 repeated permutations of the
enterovirus variable to assess the validity of the standard inference based on
the Cox regression model. All analyses were done using Stata, version 11
(StataCorp, College Station, TX). A 95% CI for the hazard ratio excluding the
value 1.00 or a P value 0.05 was regarded as statistically signiﬁcant.
RESULTS
A total of 140 children seroconverted for islet autoantibod-
ies at a median age of 4.0 years. Of those, 50 developed
type 1 diabetes at a median age of 8.7 years after a median
follow-up of 4.1 years from the initial appearance of islet
autoantibodies (Table 1). The samples tested for enterovi-
rus were collected prior to June 2007, and 41 of the 50
children had developed type 1 diabetes by that time while
another nine progressed to type 1 diabetes between June
2007 and April 2009 (Fig. 1).
Positivity for two or more islet autoantibodies at the
ﬁrst or second positive visit strongly predicted progression
to type 1 diabetes, independent of other factors (Table 1).
Those who progressed to type 1 diabetes tended to more
often carry the high-risk HLA genotype, to have a ﬁrst-
degree relative with type 1 diabetes, and to seroconvert for
islet autoantibodies at an earlier age, but these factors did
not signiﬁcantly predict progression to type 1 diabetes
independently of positivity for multiple islet autoantibod-
ies in at least one of the two ﬁrst positive visits (Table 1).
The number of positive islet autoantibodies treated as a
time-dependent variable was also highly predictive of
progression to type 1 diabetes, and positivity for ZnT8-
autoantibodies signiﬁcantly predicted progression both
before and after adjusting for the other three islet autoan-
tibodies (supplemental Table 1).
Enterovirus infections. Enteroviral RNA results were
available from serum and rectal swabs collected at 1,081
and 1,242 prediagnostic clinic visits, respectively. Results
were available for either serum or rectal swab at 1,295
visits and from both types of specimens at 1,028 visits. The
median interval between the visits was 4 months. Entero-
viral RNA was detected at a total of 54 of 1,295 visits
(4.2%). At eight of these 54 visits, enteroviral RNA was
detected in both serum and rectal swab. Of the 140
children in the cohort, 31 (22.1%) had at least one serum or
rectal swab sample positive for enteroviral RNA. While 19
of these 31 were positive only once, some had up to six
positive visits. Only two children were ever positive twice
for serum enteroviral RNA.
The prevalence of enterovirus RNA in serum or rectal
swabs declined with age from nearly 10% for the age-group
2.5 years to 1% for the age-group 7.5 years (supple-
mental Fig. 1). Enteroviral RNA tended to be more fre-
quent in boys and at visits positive for multiple islet
autoantibodies, but these differences were mostly of bor-
derline statistical signiﬁcance and not consistent among
serum and rectal swab samples (supplemental Table 2). Of
the 17 serum samples and 14 rectal swab samples col-
lected on the day of the diabetes diagnosis, none were
positive for enteroviral RNA.
Viral sequence was obtained from 8 of 17 positive serum
samples and from 33 of 45 positive rectal samples. The
sequences were deposited in the GenBank sequence data-
base under accession no. HM746666–HM746706 (supple-
mental Table 3). Sequences are shown in supplemental
Fig. 2 together with reference strain sequences listed in
supplemental Table 3. Samples on which sequencing was
not successful contained low concentrations of viral RNA.
All samples but one clustered into enterovirus genogroup
II, which contains, among others, the coxsackie B viruses
(31) (supplemental Fig. 3). The sequence data indicated
that viruses detected simultaneously in serum and rectal
samples represented the same virus strain and only a
single nucleotide substitution was once observed between
such strains. Viruses detected in successive samples taken
from the same individual represented different enterovirus
strains. Thus, no evidence of viral persistence was found.
Progression to type 1 diabetes following enterovirus
infections. The progression to type 1 diabetes in the 17
intervals following detection of enteroviral RNA in serum
was signiﬁcantly more rapid (three type 1 diabetes cases
diagnosed) than that in the 1,064 intervals following neg-
ative enteroviral RNA serum test (33 type 1 diabetes cases
diagnosed; hazard ratio [HR]6.36) (Table 2). Further ad-
justment for number of positive conventional islet autoan-
TABLE 1
Characteristics of the cohort and results of Cox regression survival analysis of progression from islet autoimmunity to type 1 diabetes
Progressed to
type 1 diabetes
(n  50)
No type 1
diabetes
(n  90)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)†
Age (years) at diagnosis of type 1 diabetes 8.7 (1.9–15)
Follow-up (years) from onset of islet autoimmunity 4.1 (0.2–11) 4.6 (1.6–14)
Positive for 2 islet autoantibodies at the ﬁrst
and/or second positive visit 36 (72%) 21 (23.3%) 4.57 (2.46–8.51) 4.24 (2.26–7.95)
Female sex 26 (52%) 48 (53.3%) 1.18 (0.67–2.06) 1.41 (0.79–2.50)
First-degree relative with type 1 diabetes‡ 35 (70%) 53 (58.9%) 1.23 (0.67–2.26) 1.13 (0.61–2.10)
HLA DRB1*04-DQB1*0302/DRB1*03-DQB1*0201 26 (52.0%) 27 (30.0%) 1.84 (1.06–3.21) 1.51 (0.86–2.67)
Non–Hispanic white ethnicity§ 46 (92.0%) 72 (80.0%) 1.94 (0.70–5.39) 1.45 (0.51–4.13)
Age (years) when ﬁrst islet autoantibody positive¶ 3.1 (0.7–12) 5.2 (0.7–13) 0.93 (0.85–1.02) 1.01 (0.091–1.11)
Data are median (range) or n (%) unless otherwise indicated. †Estimates from Cox regression model simultaneously adjusting for multiple
autoantibodies in ﬁrst two visits, HLA high risk genotype, presence of ﬁrst-degree relative with type 1 diabetes, and age when ﬁrst positive
for islet autoantibodies. ‡Of these, 35 had an affected father only, 16 had an affected mother only, 34 had an affected sibling, and 3 had a sibling
and a parent with type 1 diabetes. §Ethnic group was self-reported. There were 118 non–Hispanic whites, 19 Hispanics, one African American,
and two children of mixed ethnicity in the cohort. ¶HRs per year increase in age when ﬁrst positive for islet autoantibodies.
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three children were diagnosed in the interval after being
positive for enteroviral RNA in serum, we employed a
permutation test to make sure that the results of the
standard inference based on Cox regression were valid.
With 10,000 permutations, the (Monte Carlo) P value was
0.0075, thus conﬁrming the highly signiﬁcant result. After
restricting the analysis to the 81% of samples with avail-
able data on ZnT8 autoantibodies, there was still a signif-
icant relation between serum enteroviral RNA and
progression to type 1 diabetes (HR 6.21 [95% CI 1.82–
21.2]), and this essentially was not affected by adjustment
for ZnT8-autoantibody positivity in models without (8.50
[2.21–32.6]) or with (9.08 [2.30–35.8]) additional adjust-
ment for the number of other islet autoantibodies.
The three children who progressed to type 1 diabetes in
the interval following a positive serum enteroviral RNA
test all had typical characteristics of high risk for progres-
sion to type 1 diabetes. They had an early age at serocon-
version for multiple islet autoantibodies and an affected
sibling, and two of three carried the HLA DR3/4 genotype
(supplemental Table 4). They also had a near-average
interval length between clinic visits, and all were male and
of non–Hispanic white ethnicity. Results were similar and
remained statistically signiﬁcant after restriction of the
analysis to these respective subgroups (supplemental Ta-
ble 5). Furthermore, the results were essentially un-
changed after including four children who progressed to
type 1 diabetes after being positive only once for islet
autoantibodies (all four were negative for enteroviral
RNA, adjusted HR 6.56 [95% CI 1.84–23.5]).
Presence of enteroviral RNA in rectal swabs did not
predict progression to type 1 diabetes in the following
sample interval (adjusted HR 0.79 [95% CI 0.10–5.92])
(Table 2).
Analysis of progression to type 1 diabetes according to
the cumulative number of enterovirus infections during
follow-up, which allows for delayed effect, showed no
signiﬁcant relation with progression to type 1 diabetes for
either serum or rectal swab enteroviral RNA or for sero-
logically deﬁned infections (supplemental Table 6). We
also ran a Cox regression model simultaneously including
variables modeling enterovirus according to the rapid
effect model and the cumulative effect model. The results
conﬁrmed that the nonsigniﬁcant tendency toward an
association for the cumulative effect variable was entirely
due to the rapid effect, while the rapid effect of serum
enteroviral RNA was unaltered and still signiﬁcant (5.79
[1.23–27.3] for rapid effects model and 1.07 [0.37–3.11] for
cumulative effect model).
There was also no relation between infections deﬁned
as increases in enterovirus antibodies and progression to
type 1 diabetes according to the rapid effect model (sup-
plemental Table 7). (Note that antibodies were only tested
in the subset of samples collected during 1993–2004).
Finally, there were 19 children (61.3%) who progressed
to type 1 diabetes among the 31 with one or more
enteroviral RNA–positive serum or rectal swab samples
compared with 31 (28.4%) among the 109 children in
whom enteroviral RNA were not detected during follow-up
(P  0.001). The proportion of visits where both serum
and rectal swabs were positive for enteroviral RNA was
higher among those who progressed to type 1 diabetes (6
of 425 prediagnostic visits [1.4%]) than among nonprogres-
sors (2 of 603 visits [0.3%]), but this difference was not
statistically signiﬁcant.
DISCUSSION
To our knowledge, this is the ﬁrst study to speciﬁcally
assess the role of viral infections in the progression from
islet autoimmunity to clinical type 1 diabetes in humans.
We found that the rate of progression from islet autoim-
munity to diabetes was signiﬁcantly increased in sample
intervals (of an average of 4 months) after the detection of
enteroviral RNA in serum but not after detection of
enteroviral RNA in rectal swab samples.
Strengths and limitations. Given the amount of data
available and many possible ways of analyzing data, we
took great care to make all decisions a priori regarding
algorithms for deﬁning infections and methods of analysis.
We used a formal cohort design and employed two main
models (rapid effect and cumulative effect) to analyze two
main indicators of enterovirus infections: enterovirus RNA
in serum or in rectal swabs. Admittedly, our a priori–
deﬁned main exposure, presence of enterovirus RNA in
either serum or rectal swabs, did not signiﬁcantly predict
progression to type 1 diabetes (supplemental Table 7).
However, in preplanned subanalyses of serum and rectal
swab enteroviral RNA examined separately, we found the
presence of enterovirus RNA in serum to be a highly
signiﬁcant predictor of progression. Also, in the Finnish
TABLE 2
Progression from islet autoimmunity to clinical type 1 diabetes in sample interval (median 4 months) following infection detected
by enterovirus RNA in serum or rectal swab sample
Type of sample
Person-years
of follow-up
Cases progressing
to type 1 diabetes
in interval*
Unadjusted HR
(95% CI)
HR (95% CI) adjusted
for islet
autoantibodies
Serum
No enterovirus RNA in previous sample 494 33 1.00 (ref.) 1.00 (ref.)
Enterovirus RNA in previous sample 6.5 3 6.36 (1.89–21.4)† 7.02 (1.95–25.3)
Rectal swab
No enterovirus RNA in previous sample 537.1 32 1.00 (ref.) 1.00 (ref.)
Enterovirus RNA in previous sample 21.2 1 0.93 (0.12–6.90) 0.79 (0.10–5.92)
Data are n unless otherwise indicated. *Forty-one of 140 children in the study cohort progressed to type 1 diabetes during the period wherein
collected samples were tested for enterovirus, of which serum enterovirus RNA results were available from the clinic visit preceding
diagnosis in 36 (of which 3 were positive) and rectal swab enterovirus RNA was available in 33 (of which 1 was positive, and serum from
the same visit was also positive for enterovirus RNA). Enterovirus exposure variables coded according to the rapid effect model described
in research design and methods. †Cox regression model: P  0.003. Permutation test based on Cox regression model with 10,000
permutations of the enterovirus variable: P  0.0075.
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nity, enteroviral RNA in serum samples have been more
predictive than enteroviral RNA in stool samples (4). The
number of children who progressed in sample intervals
after the detection of viral RNA in serum was limited.
However, rather than relying on standard inference alone,
we conﬁrmed the highly signiﬁcant result using a permu-
tation test, which is not susceptible to bias with small
sample sizes. Furthermore, the result was consistent and
remained signiﬁcant in subgroups deﬁned by characteris-
tics of those who progressed to type 1 diabetes after
enteroviral RNA was found in serum.
As a marker of islet autoimmunity, we used repeated
presence of at least one islet autoantibody. This probably
does not always reﬂect insulitis or activation of autoreac-
tive T-cells, but autoantibodies are currently the best way
of predicting type 1 diabetes in humans (1).
Interpretation. Approximately 8% of the children pro-
gressing to type 1 diabetes had enteroviral RNA in their
serum a few months prior to diagnosis. While our ﬁnding
supports the hypothesis that infections resulting in entero-
viral RNA in serum lead to a more rapid progression to
clinical disease in some high-risk individuals, it may also
suggest that enterovirus infection is a relatively uncom-
mon cause of progression to type 1 diabetes. These
observations may be explained by at least three potential
scenarios.
First, we may be seeing only the tip of an iceberg
because enterovirus is normally present in blood for only
a few days during infection in immunocompetent hosts
(5,32). Thus, the sampling intervals (median 4 months) are
probably too wide to catch most of the causal infections,
and enterovirus infections could turn out to be a major
cause of progression from islet autoimmunity to diabetes.
On the other hand, while viral shedding in feces rarely
lasts more than 1 or 2 months (33), the prevalence of
enteroviral RNA in rectal swab samples collected at ages
2.5 years in the current study was of a magnitude (8.7%)
similar to that seen in other longitudinal studies with stool
samples collected monthly from healthy children aged
3–28 months in Norway (11.5%) (33) and 3–22 months in
Finland (6.0%) (34). To explain the lack of association
between enteroviral RNA in rectal swabs, we may specu-
late that not all instances of gut infection are associated
with a period with enteroviral RNA in the blood.
Second, enterovirus may establish low-grade persistent
infection in children with islet autoimmunity, but the
quantity of viral RNA in serum and feces may be below the
detection limit in most such cases. Some studies have
indicated presence of enterovirus in pancreatic tissue in a
sizeable proportion of patients dying soon after onset of
type 1 diabetes (35–38). Although the results varied de-
pending on methodology and quality of specimens, detec-
tion of enterovirus in -cells clearly strengthens the case
for its role in the pathogenesis. In addition, a recent study
suggests that the virus is present in the intestinal mucosa
of diabetic patients (39). Enteroviral RNA was only de-
tected at one time point in children diagnosed with type 1
diabetes during the sample interval following a positive
serum enteroviral RNA test, which does not support the
hypothesis of viral persistence. Sequence analysis did not
give support for persistent infection because all sequences
obtained from children with multiple infections were from
different genotypes. Furthermore, it is notable that none of
the samples collected at the day of diabetes diagnosis
were positive for enteroviral RNA. This is consistent with
a previous study of serum samples from Finland (5) but
apparently inconsistent with the majority of studies of
enterovirus RNA in plasma or serum taken from patients
soon after diagnosis, which have found 30% of patients
to be positive (40–42). We have no explanation for this
except a suggestion that an international laboratory stan-
dardization workshop could shed more light on these
differences.
Third, enterovirus infection may be just one of many
factors that can accelerate progression to diabetes, e.g.,
through nonspeciﬁc activation of autoreactive T-cells.
Additional host and environmental factors are also likely
to play a role. It is currently unclear whether certain
enterovirus serotypes are more diabetogenic in humans
than others. The most frequently implicated serotype,
coxsackievirus B4 (43), was responsible for 2.4% of the
enterovirus infectious episodes in the Norwegian study of
healthy children (33). There may also be differences within
serotypes because enteroviruses are known to mutate
rapidly (4,32).
Another possibility that cannot be discarded is that
progression to type 1 diabetes is enhanced because the
viral infection induced insulin resistance sufﬁcient to
precipitate clinical disease. Nonspeciﬁc febrile illness or
other infectious symptoms in a period prior to diagnosis
seems to be quite commonly reported, but few studies
have been able to obtain comparable data in age-matched
controls (44) and the large majority of enterovirus infec-
tions are asymptomatic (32). Furthermore, while biopsy
studies and previous cross-sectional or retrospective stud-
ies of enterovirus infections in patients with type 1 diabe-
tes cannot exclude the possibility that the disease
inﬂuenced the risk of infection, our longitudinal design
allowed us to draw stronger inference in this regard. The
fact that none of the children who were tested on the day
of diagnosis were positive for enteroviral RNA, including
those who were enterovirus positive in the interval before
diagnosis, shows that reverse causation was unlikely.
A number of potential mechanisms for how viral infec-
tions may induce or accelerate autoimmune diabetes have
been proposed, mostly based on animal models or in vitro
studies (43,45). Mechanisms in humans are likely to be
complex, but may initially involve, for example, activation
of the innate immune system, secretion of interferon-	,
and perhaps upregulation of major histocompatibility
complex molecules on -cells (46). Results from animal
models cannot automatically be generalized to humans,
but studies in strains of NOD mice have indicated a
requirement for preceding -cell damage and release of
-cell antigens taken up by antigen-presenting cells
(13,47), as previously reviewed (43). The “fertile ﬁeld
hypothesis” proposes that different viruses may increase
the risk of diabetes in susceptible time windows after an
infection, while outside this window a similar viral infec-
tion would be resolved with no further consequences for
the host (3).
Future studies and ﬁnal conclusion. Despite the huge
undertaking of screening and prospectively following a
large number of children for several years, the number of
end points was still limited and independent replication in
future studies would strengthen the results. Children who
progressed to type 1 diabetes immediately after detection
of enterovirus RNA all had clinical characteristics consis-
tent with high risk of progression such as early develop-
ment of multiple islet autoantibodies. Future studies could
investigate further the potential role of additional host and
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lenging, and up to now such studies have mainly focused
on the initiation of autoimmunity as the end point (7–9,26),
with mixed results. The Environmental Determinants of
Diabetes in the Young (TEDDY) study (48) has the poten-
tial to provide answers concerning the role of enterovirus
and progression to type 1 diabetes with greater power and
avoiding some of the limitations of the study presented
here.
In conclusion, the rate of progression from islet autoim-
munity to type 1 diabetes was signiﬁcantly increased in the
approximately 4-month interval following detection of
enteroviral RNA in serum.
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